DexCom Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 04/24/2024
DexCom Inc Stock Forecast and Price Target
If DexCom Inc's stock price reached the average yearlong target of $150.00 given by two well-known analysts in recent months, there would be a potential upside of approximately 8.8% from its last closing price in April, 2024. This potential increase is based on a high estimate of $170.00 and a low estimate of $105.00. If you're not interested in DXCM stock, you may be interested in its competitors.
8.80% Upside
DexCom Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, DexCom Inc's Price has fallen from $113.29 to $0.00 – a 100.00% decrease. In the next year, analysts believe that Fair Value will reach $210.60 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$106.89 | Buy/Sell | $118.92 | 18.35% |
| ISRG Stock Forecast | Intuitive Surgical | Outperform |
13
|
$375.01 | Buy/Sell | $408.45 | 14.66% |
| BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$72.91 | Buy/Sell | $70.14 | 8.35% |
| RMD Stock Forecast | ResMed Inc | Outperform |
17
|
$183.78 | Buy/Sell | $201.32 | 11.55% |
| VAR Stock Forecast | Varian Medical Systems | - |
16
|
$176.53 | Buy/Sell | $177.67 | -100.00% |
DexCom Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, DexCom Inc's Revenue has grown, rising from $1.93B to $3.62B – a growth of 88.01%. In the next year, analysts believe that Revenue will reach $4.14B – an increase of 14.40%. For the next seven years, the forecast is for Revenue to grow by 181.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SWAV Stock Forecast | Shockwave Medical | Hold |
4
|
$328.87 | Buy/Sell | $239.91 | 1.86% |
| PODD Stock Forecast | Insulet | Outperform |
15
|
$167.25 | Buy/Sell | $222.05 | 41.11% |
| LVGO Stock Forecast | Livongo Health | - |
0
|
$0.00 | Buy/Sell | $126.17 | 0.00% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MASI Stock Forecast | Masimo | Outperform |
14
|
$135.92 | Buy/Sell | $96.33 | 16.32% |
| INSP Stock Forecast | Inspire Medical Systems | Outperform |
6
|
$234.19 | Buy/Sell | $225.45 | 13.16% |
| ITGR Stock Forecast | Integer Holdings | Outperform |
16
|
$123.27 | Buy/Sell | $95.00 | 5.46% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AXNX Stock Forecast | Axonics | Hold |
7
|
$66.64 | Buy/Sell | $70.15 | 6.54% |
| CMD Stock Forecast | Cantel Medical LLC | - |
17
|
$0.05 | Buy/Sell | $85.00 | -100.00% |
| IRTC Stock Forecast | iRhythm Technologies | Buy |
11
|
$116.43 | Buy/Sell | $126.70 | 15.95% |
DexCom Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, DexCom Inc's EBITDA has grown by 121.26%, rising from $354.20M to $783.70M. For the next year, analysts predict that EBITDA will reach $1.14B – an increase of 44.94%. Over the next seven years, experts believe that DexCom Inc's EBITDA will grow at a rate of 172.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TMDX Stock Forecast | TransMedics Group | Outperform |
8
|
$88.88 | Buy/Sell | $90.00 | 13.64% |
| CNMD Stock Forecast | CONMED | Outperform |
16
|
$70.01 | Buy/Sell | $123.38 | 37.84% |
| TNDM Stock Forecast | Tandem Diabetes Care | Outperform |
9
|
$35.12 | Buy/Sell | $30.80 | -0.34% |
DexCom Inc EBIT Forecast for 2023 - 2025 - 2030
In the last three years, DexCom Inc's EBIT has grown, moving from $299.50M to $597.70M – an increase of 99.57%. In the next year, analysts predict that EBIT will jump to $789.91M – up 32.16% from the current level. Looking ahead to seven years, experts forecast that EBIT will grow by 327.97%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GNMK Stock Forecast | GenMark Diagnostics | - |
2
|
$0.00 | Buy/Sell | $24.05 | 0.00% |
| NTUS Stock Forecast | Natus Medical | - |
14
|
$32.96 | Buy/Sell | $36.00 | 16.60% |
| QTRX Stock Forecast | Quanterix | Outperform |
11
|
$16.04 | Buy/Sell | $32.00 | 99.50% |
DexCom Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, DexCom Inc's EPS has fallen from $0.78 to $0.00 – a 100.00% decrease. In the next year, analysts believe that EPS will reach $1.45 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SLNO Stock Forecast | Soleno Therapeutics | Buy |
0
|
$47.32 | Buy/Sell | $6.00 | 7.78% |
| SILK Stock Forecast | Silk Road Medical, Inc | Outperform |
7
|
$17.57 | Buy/Sell | $12.33 | 8.14% |
| NVRO Stock Forecast | Nevro | Hold |
6
|
$12.51 | Buy/Sell | $21.34 | 27.90% |
.jpg)